Secures $11M in Highly Dilutive Private Placement, Addresses Nasdaq Listing, Plans Reverse Split
ASBP is trading near its 52-week low of $1.21 (8.3% above the low) on light trading volume (0.1× avg).
Summary
Aspire Biopharma closed the initial tranche of a highly dilutive $21 million private placement, raising $11 million to meet Nasdaq listing requirements, with plans for a significant reverse stock split and authorized share increase.
Key Events · Financing and Capital Events · ASBP
-
Initial Closing of Private Placement
The company completed the initial closing of a private placement on February 6, 2026, issuing 13,750 shares of Series A Convertible Preferred Stock for gross proceeds of $11 million, including the conversion of $943,801 in existing debt. A second closing for up to an additional $10 million is contingent on shareholder approval and registration statement effectiveness.
-
Highly Dilutive Conversion Terms
The Series A Convertible Preferred Stock is convertible into common stock at 80% of the lowest closing price over the five trading days prior to conversion, subject to a floor price of 20% of the Nasdaq Minimum Price. This structure is highly unfavorable to existing common shareholders.
-
Addresses Nasdaq Listing Requirements
The capital raise is intended to enable the company to regain compliance with Nasdaq's stockholders' equity listing requirements, which is a critical step for continued listing.
-
Proposed Reverse Stock Split and Authorized Share Increase
The company will seek shareholder approval for a reverse stock split at a range of 1-for-5 to 1-for-500 shares, and an amendment to increase its authorized shares, typically indicative of efforts to manage share price and facilitate future capital raises.
Analysis · ASBP · Life Sciences
Aspire Biopharma Holdings, Inc. announced the initial closing of a private placement, raising $11 million through the issuance of Series A Convertible Preferred Stock. This capital raise is critical for the company to meet Nasdaq's minimum stockholders' equity requirement, providing a near-term survival pathway. However, the terms of the preferred stock are highly dilutive, allowing conversion at 80% of the lowest closing price over five trading days, with a very low floor price. This structure, often seen in distressed financings, poses a significant risk of substantial dilution for existing shareholders. The company also plans to seek shareholder approval for a reverse stock split (ranging from 1-for-5 to 1-for-500) and an increase in authorized shares, which are typically negative signals indicating efforts to maintain listing compliance and facilitate further capital raises. The filing follows a previous 8-K on February 6, 2026, which likely detailed the Certificate of Designation for the Series A Preferred Stock, and this filing provides the crucial details of the initial closing and its implications. Additionally, a director resigned, and a new director was appointed, fulfilling an investor right related to the financing.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASBP was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $1.21 to $632.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.